In Brief
Mutant huntingtin is expressed in neuronal and non-neuronal cells to cause Huntington's disease. Huang et al. demonstrate that mutant huntingtin in oligodendrocytes affects myelin gene expression and causes age-dependent neurological symptoms in transgenic mice.
INTRODUCTION
Huntington's disease (HD) is caused by polyglutamine expansion in the N-terminal region of huntingtin (Htt), a large protein that consists of 3,141 amino acids. Despite the ubiquitous expression of mutant Htt in the brain and peripheral tissues, the major pathological feature of HD is selective neurodegeneration (Vonsattel and DiFiglia, 1998; Munoz-Sanjuan and Bates, 2011) . Similarly, selective neurodegeneration is also seen in many other neurodegenerative diseases, among them Alzheimer's and Parkinson's diseases, which suggests that multiple factors may contribute to selective neurodegeneration. Given the known genetic mutation in HD and its well-characterized neuropathology, HD makes an ideal model for investigating how selective neuropathology can be caused by a disease protein that is widely expressed.
Most previous studies have focused on the effect of mutant Htt on neuronal cells and revealed that N-terminal fragments of mutant Htt are pathogenic and cause cell-autonomous or noncell-autonomous disease processes in a variety of animal models (Heng et al., 2008; Li and Li, 2012; Lee et al., 2013) . In the brain, more than 90% of cells are non-neuronal cells that provide essential support to the survival and function of neuronal cells. These non-neuronal cells consist mainly of three types of glial cells: astrocytes, microglial cells, and oligodendrocytes. Glial dysfunction has been well documented to contribute to a variety of neurodegenerative diseases. For example, oligodendrocyte dysfunction plays an important role in amyotrophic lateral sclerosis (ALS) (Fü nfschilling et al., 2012; Philips et al., 2013; Kang et al., 2013) . In HD patient brains, glial degeneration and pathology have also been documented (Rosas et al., 2003; FennemaNotestine et al., 2004; Bartzokis et al., 2007; Di Paola et al., 2012; . For example, myelin damage and breakdown were found in presymptomatic HD patients (Bartzokis et al., 2007; Phillips et al., 2014) , and white matter defects in HD patients were found to associate with motor and cognitive deficits (Bohanna et al., 2011) . Recent studies show that mutant Htt is expressed in glial cells and affects the function of astrocytes (Shin et al., 2005; Bradford et al., 2009; Tong et al., 2014) and microglial cells (Crotti et al., 2014) . For example, as in neuronal cells, mutant Htt in astrocytes can affect multiple targets, including GLT-1 to affect glutamate uptake (Shin et al., 2005; Bradford et al., 2009 ) and K channel function (Tong et al., 2014) to increase striatal neuronal excitability and vulnerability. Moreover, deficient myelination is seen in HD mouse models Xiang et al., 2011) . Nonetheless, because deficient myelination can be caused by multiple factors including neuronal and non-neuronal toxicity, whether and how mutant Htt affects the function of oligodendrocytes remain to be investigated.
The importance of investigating mutant Htt's effects in oligodendrocytes is supported by the critical role of oligodendrocytes in maintaining axonal function and early pathological changes in HD (Li et al., 2001; Wang et al., 2008; Bankston et al., 2013) . Oligodendrocytes produce myelin, which electrically insulates axons, allowing rapid and efficient propagation of nerve signals. Defective oligodendrocyte function and deficient myelination are found in numerous neurodegenerative diseases (Bankston et al., 2013) . In HD knockin (KI) mice that do not show obvious neuronal loss, axonal degeneration is an early pathologic event (Li et al., 2001) . In transgenic HD monkey brain, axonal degeneration is also seen in the absence of cell body degeneration (Wang et al., 2008) . Such axonal degeneration could be caused by mutant Htt in axons, as well as defective oligodendrocyte function. Investigating the effect of mutant Htt in oligodendrocytes will help us both understand the mechanism behind early disease pathology and develop more effective treatments.
We have established a transgenic mouse model that selectively expresses mutant Htt in oligodendrocytes. The PLP-150Q mice show obvious axonal degeneration and an earlyonset polyQ disease phenotype that includes impaired rotarod performance, body weight loss, and early death, providing strong evidence that mutant Htt in oligodendrocytes contributes to neuronal toxicity. Furthermore, we found that mutant Htt affects a newly identified transcription factor, MYRF or MRF, to reduce myelin gene expression in mature oligodendrocytes, offering new mechanistic insight into the neural dysfunction and axonal degeneration seen in HD.
RESULTS

Expression of Mutant Htt in Oligodendrocytes in HD KI Mouse
Although Htt is ubiquitously expressed in neuronal and non-neuronal cells, strong evidence for the presence of mutant Htt in oligodendrocytes is still lacking. To examine whether mutant Htt is expressed in oligodendrocytes at the endogenous level, we crossed HD 140CAG knockin (KI) mice with transgenic mice that selectively express GFP in oligodendrocytes under the control of the proteolipid protein (PLP) gene promoter (Mallon et al., 2002) , which drives transgene expression predominantly in oligodendrocytes in adult mouse brain (Michalski et al., 2011) . The crossed mice would thus allow us to define whether full-length mutant Htt is expressed in GFPpositive oligodendrocytes. Immunofluorescent staining of the crossed mouse brains showed that GFP-positive oligodendrocytes (arrows in Figure 1A ) do express mutant Htt, although their Htt staining is weaker than the neuronal staining of mutant Htt. Transgenic GFP expression in oligodendrocytes also allowed us to clearly visualize their processes. By comparing the GFPpositive processes in the cortex and striatum in wild-type (WT) and KI mice, we also saw the density of these processes reduced in the KI mouse brain ( Figures 1B and S1A ), as well as short process length ( Figure 1C ). Because these GFP-positive processes represent myelinated axons and oligodendrocyte processes (Mallon et al., 2002) , these results suggest that mutant Htt may affect the ability of oligodendrocytes to myelinate axons.
Generation of PLP-150Q Transgenic Mice that Selectively Express Mutant Htt in Oligodendrocytes
To determine whether mutant Htt in oligodendrocytes affects their function and contributes to HD neuropathology, we set out to establish transgenic mice that express mutant Htt under the control of the PLP promoter. We expressed N-terminal mutant Htt (the first 212 amino acids), including 150 glutamines in the repeat region (Htt-150Q), based on the facts that proteolysis of mutant Htt is crucial for HD pathogenesis and that N-terminal mutant Htt is misfolded and causes more severe pathology in animal models (Ehrnhoefer et al., 2011; Ross and Tabrizi, 2011; Lee et al., 2013) . For the control, we also expressed the same N-terminal Htt with 23Q (Htt-23Q) in transgenic mice (Figure 2A) . We obtained 9 positive Htt-150Q founders and 7 positive Htt-23Q founders. Western blot analysis with mEM48 showed that Htt-150Q forms aggregated Htt in the stacking gel, though its soluble level is lower than Htt-23Q in the brains of transgenic mice ( Figure 2B ). Using 1C2 antibody that reacts selectively with expanded polyQ repeats, we found that PLP-150Q is more abundant in the brain stem, striatum, and corpus callosum, which contain more oligodendrocytes than the cortex and cerebellum, in three lines of transgenic Htt-150Q mice (150Q-1, 150Q-4a, and 150Q-5). Consistent with the selective expression revealed in oligodendrocytes by the PLP promoter, there was no Htt-150Q detected in the peripheral tissues, including heart, kidney, and muscle ( Figure 2C ). Immunohistochemical analysis of the brains of 150Q-4a mice at 1, 2, and 3 months of age showed that mutant Htt is accumulated in the corpus callosum and striatum in an age-dependent manner ( Figure 2D) . Because of the similar expression levels of transgenic Htt in different mouse lines, we focused on the 150Q-4a (simply named PLP-150Q) and 23Q-4 (named PLP-23Q) lines for more detailed characterization.
Immunohistochemical studies showed that mutant Htt is restricted in areas that are enriched in oligodendrocytes, such as the corpus callosum, and appears to be localized in the nuclei (Figures S1B and S1C). Compared with HD140Q KI mice, in which mutant Htt is ubiquitously expressed in neuronal and glial cells, PLP-150Q mice showed the selective distribution of mutant Htt in glial cells and less abundant aggregates (Figure S1D ). Using primers specific for human Htt, we performed qRT-PCR to compare the mRNA expression levels of transgenic Htt. Compared with mutant Htt in HD140Q KI mice at the endogenous level, transgenic Htt mRNA was slightly higher (Figure S2A) . However, western blotting revealed that transgenic mutant Htt in the striatum and brain stem is expressed at a lower protein level than mutant Htt in HD140Q KI mouse brain ( Figure S2B ).
To verify that transgenic mutant Htt is indeed localized in the nuclei of oligodendrocytes, we crossed PLP-150Q mice with PLP-GFP mice. As expected, transgenic mutant Htt is abundantly distributed in the white matter region (corpus callosum) between the cortex and striatum and is localized in the nuclei of GFP-positive oligodendrocytes ( Figure 3A) . Using anti-olig2 and anti-Htt antibodies for immunofluorescent double labeling, we confirmed that mutant Htt accumulates and forms aggregates in the nuclei of oligodendrocytes in adult PLP-150Q mouse brain ( Figure 3B ). Importantly, none of these aggregate-containing cells could be labeled by antibodies to the astrocyte-specific protein, GFAP, or the neuronal protein, NeuN ( Figure 3C ). These results taken together show that we have established transgenic mice that express transgenic Htt specifically in mature oligodendrocytes.
Progressive Neurological Phenotypes of PLP-150Q Mice Transgenic mice (PLP-23Q and PLP-150Q) generated from F1 were born normally. They can be bred normally as WT mice and do not show obvious behavioral abnormalities and motor deficits during postnatal developmental stage and before 2 months of age. However, PLP-150Q mice develop age-dependent neurological symptoms starting at 3 months. We found that old PLP-150Q mice at age of 5 months display a clasping phenotype and reduced body weight compared with PLP-23Q mice ( Figure 4A ). PLP-150Q mice at 5 months of age also have tremors and difficulty walking (Movie S1). The body weight of PLP-150Q mice began to decrease at the age of 4 months and continued to decrease progressively ( Figure 4B ). As a result, PLP-150Q mice started to die at 5 months of age and could not live longer than 10 months ( Figure 4C ). Consistent with their severe body weight loss and early death, PLP-150Q mice showed a significant deficit in their motor function as measured by rotarod performance, and this motor dysfunction became progressively worse with age ( Figure 4D ). We also compared different PLP-150Q mouse lines at a young age (2 months) and found that all of these mouse lines had poor rotarod performance ( Figure 4E ). The locomotor activity of PLP-150Q mice is also lower than PLP-23Q and WT mice during their active times zone (7 p.m. to 11 p.m.) ( Figure 4F ). Because mutant Htt is expressed in oligodendrocytes, it may cause dysfunction of these cells and affect axonal conductivity, which may alter the susceptibility to seizure insults; thus, we next measured the latency of mice to generalized seizure induced by flurothyl and found that PLP-150Q mice were more sensitive to seizure induction ( Figure 4G ).
Axonal Degeneration and Reduced Myelin Gene Expression in PLP-150Q Mouse Brain
Next, we wanted to examine whether mutant Htt in PLP-150Q mice causes any myelination defect or axonal degeneration. The PLP-150Q/PLP-GFP crossed mice allowed us to examine the integrity of oligodendrocyte processes. We found that there is indeed reduced oligodendrocyte process length and no difference in the number of oligodendrocytes, in PLP-150Q mice (Figure 5A) . Electron microscopy revealed that myelinated axons in the striatum of PLP-150Q and PLP-23Q mice at the age of 1 and 2 months are not distinguishable. However, at 3 months, there was a reduction of myelination in axons in PLP-150Q mice compared with PLP-23Q mice, and this reduction became more severe at 5 months ( Figure 5B ). Quantitative analysis of g ratios (the inner axonal diameter to the total outer diameter) confirmed that mutant Htt significantly increased this ratio in PLP-150Q mice in an age-dependent manner ( Figure 5C ). It is well known that demyelination can lead to axonal degeneration (Rodriguez and Scheithauer, 1994; Sathornsumetee et al., 2000; Lee et al., 2014) . Consistently, electron microscopy also revealed a number of degenerated axons, which appear swollen and dark, in PLP-150Q mice at 5 months of age ( Figure 5D ). The obvious axonal degeneration was not seen in 3-month-old PLP-150Q mice, suggesting that this degeneration occurs after demyelination ( Figure S2C ). We also obtained HD patient brains that contain 45 to 53 CAG repeats in the HD gene (Table S1 ). Although the ultrastructure of postmortem brain tissue was not well preserved, we were able to identify demyelinated axons in the HD patient brain compared with the control individual that did not die of neurodegenerative diseases ( Figure S2D ).
Mutant Htt Reduces the Expression of Myelin Proteins
To understand how mutant Htt affects myelination, we performed microarrays aiming to identify molecules likely to be involved in Htt-mediated toxicity. Microarray analysis of gene expression in PLP-150Q mouse spinal cord at 3 months revealed 998 significantly upregulated and 152 significantly downregulated genes in PLP-150Q compared with WT mice (Figures S3A and S3B) . Of these potentially altered genes, many are important for lipid metabolism, cell death, and proliferation ( Figure S3C) ; their altered expression could be secondary responses to demyelination and axonal degeneration. Myelin synthesis requires cholesterol (Saher et al., 2011) , and lipid metabolism is mediated by the transcription factor PGC1a (Camacho et al., 2013) . Previous studies showed that the expression of PGC1a and the homeostasis of cholesterol are affected in HD mouse models (Xiang et al., 2011; Valenza and Cattaneo, 2011) . qRT-PCR analysis of PGC1 a, cholesterol transport (StarD4), and sterol regulatory element binding transcription factor 2 (SREBF2) revealed no significant differences in their expression in the striatum of PLP-23Q and PLP-150Q mice ( Figure S3D ). Further, using GFP-positive oligodendrocytes that were isolated via fluorescence-activated cell sorting from double transgenic mice expressing GFP and transgenic Htt in oligodendrocytes, we did not see significant differences in the expression levels of PGC1a, StarD4, and SREBF2 between WT, PLP-23Q, and PLP-150Q mice (Figures S4A and S4B) . It has been reported that MCT1, the monocarboxylate transporter 1 that is responsible for releasing lactate and ketone bodies from oligodendrocytes, is affected in ALS (Lee et al., 2012) . We performed both qRT-PCR and western blotting assays but could not see a significant defect in its expression in PLP-150Q mouse brains ( Figures S4C and S4D ). Taken together, these results suggest that when mutant Htt is selectively expressed in oligodendrocytes, it may affect the expression of selective genes via different mechanisms.
Because there is a marked defect in myelination in PLP-150Q mice, we performed western blotting to detect the expression of myelin proteins, such as the oligodendrocyte-specific proteins 2 0 , 3 0 cyclic nucleotide 3 0 -phosphodiesterase (CNP), myelin basic protein (MBP), myelin-associated oligodendrocytic basic protein (MOBP) and myelin oligodendrocyte glycoprotein (MOG), in the mouse brain and found that their expression is upregulated from postnatal day 14 ( Figure 6A ). Importantly, mutant Htt does not affect the postnatal expression of myelin proteins at postnatal day 14. However, at 1 month, PLP-150Q mice showed decreases in the expression of these oligodendrocyte-specific proteins, in both the striatum and brain stem ( Figures 6B, 6C , S5A, and S5B). Importantly, these decreases are age dependent and became more significant when PLP-150Q mice were 6 months old and were also seen in different PLP-150Q mouse lines (Figures 6 and S5C ). To further verify that the reduced expression of MBP is due to the effect of nuclear mutant Htt on gene transcription, we performed qPCR. Results confirmed the reduction in MBP mRNA in PLP-150Q mouse brains ( Figure 6D ). To test if reduced MBP also occurs in the brains of HD patients, we performed both qRT-PCR ( Figure 6E ) and western blot analyses ( Figures 6F and 6G) . The results indicate that MBP is indeed decreased at both mRNA and protein levels in HD patient brains.
Because there were no significant decreases in these proteins in the PLP-150Q mouse brains at 1 month, mutant Htt may not have an impact on these proteins during development but may affect mature oligodendrocytes in adult mouse brains. In support of this idea, oligodendrocyte transcription factor (OLIG2), which is also expressed in undifferentiated oligodendrocytes and their precursors (Ligon et al., 2006; Meijer et al., 2012) , is not affected significantly by mutant Htt. To further verify the selective effect of mutant Htt in adult mouse brains, we examined the expression of neuronal and glial marker proteins in postnatal mouse brains. Western blot results revealed no alteration of these proteins in PLP-150Q mouse brains at P1, P7, and P14 ( Figure S6A ). Both western blot and immunocytochemical analyses did not detect either caspase-3 activation or increased GFAP (Figures S6A and S6B) . Immunocytochemical analyses of NeuN and olig2 staining also support the western blot results, which demonstrate the unaltered expression of these neuronal and oligodendrocyte-specific proteins in PLP-150Q mouse brains (Figure S6C) . By counting the number of Olig2-positive cells (WT: 268.000 ± 4.626; 23Q: 262.333 ± 8.939; 150Q: 272.333 ± 6.726; n = 3 mice/group) and NeuN (WT: 1263.333 ± 45.507; 23Q: 1292.667 ± 65.787; 150Q: 1201.333 ± 27.591; n = 3 mice/group), we did not find any difference between WT, PLP-23Q, and PLP-150Q mice at P14. In addition, we did not find that mutant Htt affects proliferation of glial cells in the corpus callosum of PLP-150Q mice and differentiation of cultured oligodendrocytes from PLP-150Q mice ( Figure S7 ). All these results support the idea that mutant Htt affects the expression of myelin genes in an age-dependent manner, which is consistent with the aging-related and progressive symptoms of HD mice.
Mutant Htt Binds N-Terminal MYRF and Affects Its Transcription Activity
The decrease in several oligodendrocyte-specific proteins led us to focus on the transcription factors that mediate the expression of these proteins. Recently, myelin regulatory factor (MYRF) was found to regulate the expression of myelin-specific proteins (Emery et al., 2009; Hornig et al., 2013) . MYRF is not expressed in oligodendrocyte precursors (OPCs) (McKenzie et al., 2014) but expressed only in postmitotic oligodendrocytes (Cahoy et al., 2008) , and its depletion in oligodendrocytes causes failures in myelin gene expression and myelin formation (Emery, 2010) . However, western blotting showed that MYRF is not decreased in the brains of PLP-150Q mice ( Figure 6B ). Because mutant N-terminal Htt is able to interact with a number of transcription factors in neuronal cells (Harjes and Wanker, 2003; Li and Li, 2004) , we wanted to know whether mutant Htt interacts with MYRF and affects myelin gene expression. To that end, we first generated the plasmid encoding mouse MYRF and expressed it in transfected HEK293 cells. We found that MYRF is unstable and cleaved to a smaller N-terminal fragment, which is labeled by an antibody against the N-terminal region of MYRF (Figure 7A ). This finding is consistent with the recent report that MYRF can be self-cleaved (Bujalka et al., 2013; Li et al., 2013) . Treatment of cells with the proteasome inhibitor MG132 significantly increased the expression levels of full-length MYRF and its cleaved products ( Figure 7B ). Using brain tissues of HD KI mice that express full-length mutant Htt at the endogenous level, we performed Htt immunoprecipitation and found that more N-terminal MYRF (nMYRF) was also co-precipitated with mutant Htt ( Figure 7C ). To verify that this in vivo interaction also occurs in our transgenic Htt mouse brain tissues, we performed Htt immu- noprecipitation and found that mutant Htt could co-precipitate more nMYRF than full-length MYRF ( Figure 7D ).
Although the above immunoprecipitations demonstrate the in vivo interaction of MYRF with mutant Htt, it remains unclear whether mutant Htt binds more nMYRF than normal Htt as the antibodies (mEM48 and 1C2) we used for immunoprecipitation and western blotting preferentially reacts with mutant Htt and precipitates more mutant Htt. To examine whether mutant Htt binds abnormally to MYRF, we used transfected cells to express N-terminal Htt and MYRF for studying their interactions. We generated nMYRF tagged with the Myc epitope and C-terminal MYRF (cMYRF) tagged with the FLAG epitope ( Figure 7E ). Transfection of these two proteins in HEK293 cells confirmed that nMYRF is localized in the nucleus, and cMYRF is in the cytoplasm ( Figure 7F ). These results are in agreement with recent findings that nMYRF, once generated from the self-cleavage of full-length MYRF, is able to translocate into the nucleus to execute its transcription function (Bujalka et al., 2013; Li et al., 2013) .
By co-expressing nMYRF or cMYRF with NLS-tagged N-terminal Htt (1-212 amino acids) containing 23Q or 150Q in HEK293 cells and performing immunoprecipitation of transfected MYRF, we found that more Htt-150Q was precipitated by nMYRF when the same levels of Htt-23Q and Htt-150Q were present in the input ( Figure 8A ). In contrast, immunoprecipitation of cMYRF failed to precipitate transfected Htt ( Figure 8B ). These results support the in vivo interaction of mutant Htt with nMYRF in HD mouse brains ( Figures 7C and  7D ). To further verify that mutant Htt can interact with MYRF directly, we performed an in vitro binding assay using in vitro synthesized Htt incubated with GST-nMYRF fusion proteins. The result also showed that more mutant Htt bound to GST-nMYRF than normal Htt ( Figure 8C ). By expressing different fragments of MYRF with mutant Htt in transfected cells and co-immunoprecipitation, we found that nMYRF containing the proline-rich domain interacts with Htt and that polyQ expansion could increase this interaction (Figure S8A-D) . Because nMYRF has transcriptional activity, the binding of mutant Htt to the N-terminal region of MYRF also supports the idea that this interaction affects the transcription activity of MYRF. Also, the interaction between mutant Htt and MYRF suggests that soluble mutant Htt binds MYRF, which is supported by immunofluorescent staining of transfected cells in which soluble MYRF is diffuse with mutant Htt in the nucleus, but is not colocalized with Htt aggregates ( Figure S8E ).
On the basis of the above findings, we went on to test whether mutant Htt affects the transcription activity of MYRF. For this assay, we isolated the promoter region of the mouse MBP gene on the basis of an earlier finding (Mack et al., 2007) and linked this promoter with the luciferase reporter. An assay of luciferase reporter activity showed that MYRF significantly increased the MBP promoter activity, which was inhibited by mutant Htt (Figure 8D ). Importantly, nMYRF, but not cMYRF, could also stimulate the MBP promoter activity and reverse the inhibition caused by mutant Htt (Figure 8E) . Via chromatin immunoprecipitation (ChIP) assay, we immunoprecipitated nMYRF associated-DNAs in the presence of normal and mutant Htt and measured the associated MBP promoter DNAs using qPCR. We found that mutant Htt significantly inhibited the association of nMYRF with the MBP promoter (Figure 8F) . These results support the idea that mutant Htt binds nMYRF to affect its transcription activity by altering its association with DNAs. On the basis of the fact that MYRF is self-cleaved to nMYRF, which is then translocated into the nucleus to activate myelin gene expression (Bujalka et al., 2013; Li et al., 2013) , we propose a model in which N-terminal mutant Htt accumulates in the nuclei of oligodendrocytes in an age-dependent manner. This age-related accumulation causes mutant Htt to bind nMYRF in mature oligodendrocytes and affects its transcription activity, resulting in decreased expression of myelin genes and an associated myelination deficiency and axonal degeneration in HD ( Figure 8G ).
DISCUSSION
By establishing transgenic mice that express mutant Htt selectively in oligodendrocytes, we provide strong evidence for the important contribution of mutant Htt in oligodendrocytes to HD neuropathology. We also show that mutant Htt can affect cell type-specific gene expression to reduce myelin gene (legend continued on next page) expression, leading to axonal degeneration. In addition, we find that mutant Htt affects MYRF transcription activity via its abnormal association with MYRF, providing mechanistic insight into the specific effect of mutant Htt on a particular type of nonneuronal cell.
Although transgenic mice expressing N-terminal mutant Htt are valuable models for exploring the pathogenesis of HD, whether their pathological characteristics can be replicated in HD mouse models that express full-length mutant Htt merits discussion here. All full-length Htt HD mouse models, transgenic or KI, show milder disease progression than transgenic mice expressing N-terminal mutant Htt (Menalled and Chesselet, 2002; Heng et al., 2008) . Because only N-terminal mutant Htt is able to misfold and form aggregates, proteolysis of full-length mutant Htt has been widely held to be an important process toward HD pathogenesis (Ehrnhoefer et al., 2011; Lee et al., 2013; Ross et al., 2014) . In this regard, the expression of N-terminal mutant Htt can facilitate disease progression and yield robust phenotypes in mice, allowing us to identify pathogenic pathways and evaluate therapeutic targets (Menalled and Chesselet, 2002; Heng et al., 2008) . One good example is that young R6/2 mice at 3 to 4 months of age, which express exon1 mutant Htt, recapitulate many pathological changes seen in the end stage of HD KI mice at 2 years of age (Woodman et al., 2007) .
Mutant Htt affects the function of neuronal and glial cells in the brain. Because HD pathogenesis involves cell-autonomous and non-cell-autonomous toxicity of mutant Htt (Gu et al., 2005) , generating animal models with cell type-specific expression of mutant Htt is important to dissect HD pathogenesis. In our PLP-150Q transgenic mice, we saw that mutant Htt in oligodendrocytes forms aggregates in their nuclei, interacts with the oligodendrocyte-specific transcription factor, MYRF, and reduces myelin gene expression. All these important pathogenic events were also seen in HD KI mouse brains. Moreover, the effect of mutant Htt on axons in PLP-150Q mice is consistent with our early findings that axonal degeneration is seen in the brains of a HD KI mouse model (Li et al., 2001 ) and transgenic monkey brains (Wang et al., 2008) . Oligodendrocytes and myelin abnormalities can slow or stop fast axon transport, resulting in synaptic loss and axonal degeneration (Han et al., 2010) . Our PLP-150Q mouse model supports the idea that axonal degeneration can also be caused by the non-cell-autonomous toxicity of mutant Htt in oligodendrocytes.
That said, however, PLP-150Q mice develop much more progressive and severe phenotypes, even when mutant Htt is selectively expressed in oligodendrocytes. Such severe phenotypes are unlikely to be due to the overexpression of N-terminal mutant Htt, because the level of Htt-150Q is lower than the control transgenic Htt-23Q, which did not elicit any neurological phenotypes.
Also, other transgenic HD mouse models expressing N-terminal mutant Htt at levels lower than endogenous mouse Htt in either astrocytes or axonal terminals show early death and progressive phenotypes (Bradford et al., 2009 : Xu et al., 2013 . All these findings suggest that once N-terminal mutant Htt accumulates in oligodendrocytes, it can greatly facilitate disease progression.
Our identification of the effect mutant Htt has on MYRF-mediated myelin gene expression is consistent with the findings that N-terminal mutant Htt can interact with a number of transcription factors and affect gene transcription (Harjes and Wanker, 2003; Li and Li, 2004) . A new insight from our study is that the transcription dysfunction in oligodendrocytes is both cell type specific and protein context dependent. Our findings also suggest that mutant Htt affects the function of mature oligodendrocytes. The accumulation of N-terminal mutant Htt in the nuclei of mature oligodendrocytes in adult mice is age dependent, as evidenced by the following facts: (1) PLP-150Q mice show increased accumulation of mutant Htt in the adult brain with aging, (2) PLP-150Q mice display demyelination and reduced myelin gene expression in an age-dependent manner, and (3) PLP-150Q mice develop age-dependent and progressive neurological symptoms. Perhaps in mature oligodendrocytes, mutant Htt is prone to accumulating in their nuclei, thereby affecting gene expression. Consistent with these facts, we also found that mutant Htt did not affect the survival of neuronal cells and oligodendrocyte proliferation during early postnatal development. Although the PLP promoter was found to drive gene expression in different types of cells during embryonic and early developmental stages, transgenic gene expression under this promoter becomes restricted to oligodendrocytes in adult mouse brain (Michalski et al., 2011) . Mutant Htt-mediated toxicity in oligodendrocytes requires an age-dependent accumulation of misfolded Htt in cells. It is likely that mature oligodendrocytes are less capable of clearing misfolded N-terminal Htt than undifferentiated precursor cells. Thus, the expression of N-terminal mutant Htt, which is prone to misfolding, even at a low level, could greatly facilitate the accumulation of the toxic form of mutant Htt in oligodendrocytes, whereas in HD KI mice, it takes a much longer time to accumulate N-terminal mutant Htt after being generated by the proteolysis of full-length mutant Htt.
The idea that mutant Htt affects the expression of selective genes in mature oligodendrocytes is also supported by the fact that mutant Htt does not reduce the expression of OLIG2, which is expressed predominantly in OPC cells and undifferentiated oligodendrocytes. Because OLIG2 is also present in mature oligodendrocytes and MYRF is restricted to mature oligodendrocytes (Cahoy et al., 2008; Emery et al., 2009) , the negative impact of mutant Htt on OLIG2 is consistent with the finding that OLIG2 (E) Expression of nMYRF, but not cMYRF, could rescue the inhibitory effect of mutant Htt on the MBP promoter activity. *p < 0.05; **p < 0.01; ***p < 0.001. Data are mean ± SEM. (F) qPCR quantification of the MBP promoter DNAs associated with Myc-nMYRF that was immunoprecipitated by anti-Myc in ChIP assay. The results were obtained from three independent experiments. **p = 0.019. Data are mean ± SEM. (G) A proposed model for the effect of mutant Htt in oligodendrocytes. According to recent studies (Bujalka et al., 2013; Li et al., 2013) , full-length MYRF is selfcleaved to nMYRF, which is dissociated from ER and translocalized to the nucleus to activate the expression of myelin genes. In HD, the accumulation of N-terminal mutant Htt in the nucleus can lead to the abnormal binding of nMYRF and affects its transcription activity, leading to reduced expression of myelin genes and oligodendrocyte dysfunction. expression is not mediated by MYRF (Emery et al., 2009 ) and indicates a specific effect of mutant Htt on MYRF. Another line of evidence to support the specific effect of mutant Htt in oligodendrocytes is the negative impact of mutant Htt on the expression of MCT1. MCT1 transports lactate from oligodendrocytes to support neuronal survival and was found to be reduced in oligodendrocytes in ALS mouse brains (Lee et al., 2012) . Because mutant SOD1 in ALS is expressed largely in the cytoplasm, the cytoplasmic effect of mutant SOD1 may reduce the expression of MCT1, which is different from the nuclear effect of mutant Htt, via a different mechanism.
Because oligodendrocytes are critical for axonal function and are also a desirable transplant population for remyelination strategies, the findings from our study provide a new therapeutic target for treating HD. Oligodendrocytes are generated mostly during the postnatal periods (P7-P14) in rodents. These cells differentiate from proliferative, migratory OPCs and produce myelin proteins required for myelination. Although most myelination occurs early in life, myelination processes may exhibit substantial plasticity in adult brains and have evolved to combat a range of infectious, metabolic, and immune insults, which can cause demyelination and lead to multiple sclerosis (Paus et al., 1999; Franklin and Ffrench-Constant, 2008; Emery, 2010) . A recent study demonstrates that depletion of MYRF prevents adult myelination, reduces the production of new oligodendrocytes during adulthood, and affects motor skill learning in mice (McKenzie et al., 2014) . Newly differentiated oligodendrocytes are widely thought to generate additional myelin (Franklin and Ffrench-Constant, 2008; Emery, 2010) , and on the basis of this idea, approaches to promote differentiation of OPCs into myelinating oligodendrocytes have been hotly pursued for the treatment of demyelination-related pathology (Rivers et al., 2008; Boulanger and Messier, 2014) . Our studies indicate that mutant Htt affects mature oligodendrocytes to cause a decrease in myelin proteins and subsequent loss of myelin, suggesting that the production of myelin proteins in mature oligodendrocytes is important for the maintenance of myelin in adult brains as well (Koenning et al., 2012 ). This idea is also supported by the finding that mutant Htt does not reduce Olig2 but rather affects the function of MYRF, which is expressed only in postmitotic oligodendrocytes (Cahoy et al., 2008; Emery et al., 2009; McKenzie et al., 2014) . The findings of our study therefore suggest that improving the function of mature oligodendrocytes should at least be beneficial in HD and perhaps other age-dependent neurodegenerative diseases that involve the dysfunction of mature oligodendrocytes and associated axonal dysfunction as well.
EXPERIMENTAL PROCEDURES Animals
To generate PLP-Htt transgenic mice, cDNA encoding N-terminal human Htt (amino acids 1-212) containing 23Q or 150Q was subcloned into the pNEB193 vector using BamHI and XbaI. The plasmid was then digested with PmeI and AscI, and the Htt-containing fragment was inserted into the PLP promoter cassette. The pNEB193 vector and PLP promoter cassette were generated previously (Fuss et al., 2000) . Pronuclear injection of the linearized construct was performed by the Transgenic Mouse and Gene Targeting Core at Emory University. Founder mice were obtained and maintained at the Emory mouse facility. Genomic DNA was isolated from mouse tails, and PCR genotyping with primers that flank the polyQ region was used to screen for transgenic mice. The sequences of the primers are as follows: forward, 5 0 -ATGAAG GCCTTCGAGTCCCTCAAGTCCTTC-3 0 , and reverse, 5 0 -AAACTCACGGTCGG TGCAGCGGCTCCTCAG-3 0 . We identified nine positive PLP-150Q founders and seven positive PLP-23Q founders. Transgene expression was determined via western blotting. PLP-GFP mice were obtained from Dr. Wendy Macklin (University of Colorado Denver) and bred with PLP-Htt mice to generate double-transgenic mice. Full-length mutant Htt CAG140Q (HD KI) mice were provided by Dr. Michael Levine (University of California, Los Angeles). All mice were bred and maintained in the animal facility at Emory University under specific pathogen-free conditions in accordance with the institutional guidelines of the Animal Care and Use Committee at Emory University.
Mouse Behavior Analysis
Mouse body weight was measured once every month, and survival was monitored regularly. The motor function of the mice was assessed with the rotarod test (Rotamex; Columbus Instruments). Mice were trained on the rotarod at 5 rpm for 5 min for 3 consecutive days. After training, the mice were tested for 3 consecutive days, three trials per day. The rotarod gradually accelerated to 40 rpm over a 5 min period. Latency to fall was recorded for each trial. At least 15 mice were analyzed per group when comparing PLP-150Q, PLP-23Q, and WT. When comparing all PLP-150Q lines, at least 5 animals were analyzed per group. The flurothyl-induced seizure experiment was performed as previously described (Makinson et al., 2014) . Mice were placed in a clear Plexiglas chamber and exposed to flurothyl (2,2,2-trifluroethylether) (Sigma, 287571) at a rate of 20 ml/min. Latency to generalized seizure was recorded. Mice were at least 3 months old, and at least ten animals were analyzed for each group. Locomotor activity was assessed using an automated system (PAS; San Diego Instruments) that records all photobeam interruptions. Each mouse was housed in a separate chamber with food and water. Activity was recorded once every 30 min for 30 hr. The first 6 hr were excluded from analysis. At least eight animals were analyzed per group.
Immunofluorescence, Immunohistochemistry, and Electron Microscopy Mice were anaesthetized with 5% chloral hydrate and perfused with 0.9% NaCl, followed by 4% paraformaldehyde (PFA). The brains were removed and post-fixed in 4% PFA overnight at 4 C. The brains were transferred to 30% sucrose for 48 hr, then cut to 20-or 40-mm sections with the cryostat (Leica CM1850) at À20 C. Sections were blocked in 4% donkey serum with 0.2% Triton X-100 and 3% BSA in PBS for 1 hr. For immunofluorescent staining, 20 mm sections were incubated with primary antibodies in the same buffer at 4 C overnight. After washing with 1X PBS, the sections were incubated in fluorescent secondary antibodies and Hoechst stain. Fluorescent images were acquired with a Zeiss microscope (Carl Zeiss Imaging, Axiovert 200 MOT) and either a 403 or 633 lens (LD-Achroplan 403/0.6 or 633/0.75) with a digital camera (Hamamatsu, Orca-100) and Openlab software (Improvision). For immunohistochemistry with DAB staining, after blocking, 40 mm sections were incubated with mEM48 for at least 48 hr at 4 C. A biotin/avidin immunoassay (Vector Laboratories) and DAB kit (Invitrogen, 00-2020) were used. Images were acquired with a Zeiss microscope (Carl Zeiss Imaging, Imager A.2) and either a 403 or 633 lens (Plan-Apochromat 403/0.95 or 633/1.4) with a digital camera (Carl Zeiss Imaging, AxioCam HRc) and AxioVision software. For electro-microscope study, mice were perfused with 0.9% NaCl followed by 4% PFA containing 2.5% glutaraldehyde. After post-fixation, the brain was cut to 50-mm sections using the vibratome (Leica, VT1000). The sections were processed as previously described (Wang et al., 2008) . Axon and myelin fiber diameters were measured using ImageJ (NIH). More than 300 axons were examined for each genotype.
Statistical Analysis
Results are expressed as mean ± SEM. Prism6 (GraphPad Software) was used for statistical analysis. When only two experimental groups were compared, Student's t test was used to calculate statistical significance. For all other experiments, statistical significance was calculated using one-way ANOVA or two-way ANOVA, followed by Tukey's multiple-comparisons test. A p value <
